BUFFALO, N.Y., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company
dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related
conditions, today announced that it will release third quarter 2018 and nine months ended September 30, 2018 earnings results on
November 14, 2018 before the market opens. The Company will host a conference call and live audio webcast on Wednesday, November
14, 2018 at 8:00 a.m. Eastern Time to discuss the financial results and provide a business update.
To participate in the call, dial 877-407-0784 (domestic) or 201-689-8560 (international) fifteen minutes before the conference
call begins and reference the conference passcode 13683946. A replay of the call will be accessible two hours after its completion
through November 21 by dialing 844-512-2921 (in the U.S.) or 412-317-6671 (outside the U.S.) and entering passcode 13683946.
The live conference call and replay can also be accessed via audio webcast at the Investor Relations section of the Company’s
website, located at www.athenex.com.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery
and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an
Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. The Company’s current clinical pipeline is
derived from four different platform technologies: (1) Orascovery, based on non-absorbed P-glycoprotein inhibitor, (2) Src kinase
inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex’s employees worldwide are
dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in
Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan and multiple
locations in Chongqing, China. For more information, please visit www.athenex.com.
CONTACTS
Investor Relations:
Tim McCarthy
Managing Director, LifeSci Advisors, LLC
Tel: +1 716-427-2952
Direct: +1 212-915-2564
Athenex, Inc.:
Randoll Sze
Chief Financial Officer
Email: randollsze@athenex.com
Jacqueline Li
Email: jacquelineli@athenex.com
